News Digest / Samuel Brooks

Author: Samuel Brooks

05:32pm, Thursday, Feb 13, 2025
Company Overview:Vistagen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing novel intranasal therapies targeting neuropsychiatric disorders. Recent Financial Performance: Net Loss: Net loss for Q3 2024 was $14.1 million, an increase from $6.4 m...